NEW YORK, July 27- Cellomics, a Pittsburgh-based maker of cell-imaging technology, said recently that it sold its ArrayScan HCS System to Vertex Pharmaceuticals of Cambridge, Mass.

The ArrayScan Sytem is an automated system designed to measure and analyze cell activity as a way of determining function. The system can also be used to determine whether a drug is toxic or efficacious, Cellomics said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.